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Cellular therapy is a promising tool for improving the outcome of organ
transplantation. Various cell types with different immunoregulatory and
regenerative properties may find application for specific transplant rejec-
tion or injury-related indications. The current era is crucial for the devel-
opment of cellular therapies. Preclinical models have demonstrated the
feasibility of efficacious cell therapy in transplantation, early clinical trials
have shown safety of several of these therapies, and the first steps towards
efficacy studies in humans have been made. In this review, we address the
current state of the art of cellular therapies in clinical transplantation and
discuss monitoring tools and endpoints for these studies.
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Introduction
The implementation of calcineurin-inhibiting drugs
with immune cell proliferation inhibitors in clinical
transplantation practice in the 1980s and 1990s has
greatly advanced the outcome of organ transplantation
[1–3]. In particular, short-term graft survival improved
dramatically after the introduction of these drugs. How-
ever, long-term graft survival did not see the same
improvement, and furthermore, long-term use of
immunosuppressive drugs has been indicated to lead to
chronic deterioration of graft function, in particular of
the kidney [4]. Therefore, there is a need for alternative
therapies that are capable of improving long-term graft
survival without side effects that can be used in con-
junction with or even replace conventional therapy. In
this perspective, cellular therapy is of major interest.
Medicines based on cells may possess these properties.
Different than immunosuppressive drugs, a single
administration of cells could potentially have long-term
effects, and while cells may have infusion-related
adverse effects, there is so far little evidence for long-
term toxicity effects. There are multiple cell types with
immunomodulatory properties, and there are cell types
that have in addition the potential to stimulate regener-
ative processes. Not all cell types are suitable for therapy
development. Therapeutic cells need to be able to
expand in vitro unless therapeutic amounts of cells can
be harvested from a donor, and survive cryopreserva-
tion when applied, and they should allow safe routes of
administration. When considering allogeneic cell thera-
pies, the immunogenicity of the cells becomes a relevant
issue.
A number of cell types possess suitable properties for
the development of therapies and have been studied for
their applicability and efficacy in organ transplantation.
These include mesenchymal stromal cells (MSC), regu-
latory T cells, regulatory macrophages and tolerogenic
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dendritic cells, which are mainly studied for their
immunoregulatory properties. Functional cell types,
such as hepatocytes, may find use for replacement of
nonfunctional tissue cells. Potentially, cell replacement
can substitute organ transplantation although there are
challenges with engraftment of functional cell types. It
has been demonstrated that radiation preconditioning
of the liver may improve the engraftment of hepatocytes
[5]. The organ transplantation field may draw inspira-
tion from studies in Duchenne syndrome, which explore
the replacement of satellite stem cells in the muscle with
gene-corrected induced pluripotent stem cells (iPSCs)
differentiated into satellite stem cells [6]. In organ
transplantation, regenerative cell therapy is mostly
aimed at activation of resident progenitor cells. Thera-
peutic cells actively secrete regenerative compounds and
furthermore release vesicles that are loaded with pro-
teins and RNA, which may themselves be used as a
form of cell-derived therapy. Cells can also be used to
generate implantable bio-engineered tissues and orga-
noids in vitro. Using cell reprogramming techniques and
by mimicking embryological conditions in a culture
dish, remarkable differentiated organoids can be gener-
ated that resemble kidney [7], liver [8], intestine [9]
and other transplantable organs. These organoids find
use for disease modelling and drug testing and eventu-
ally may be used for replacement of nonfunctional tis-
sue. There is excellent literature on this topic [7,10,11].
The present review focuses on cellular therapies that can
be administered to modulate alloimmune responses and
initiate transplant organ regenerative processes in the
transplant patient.
Mesenchymal stromal cell therapies
The first studies with MSC in clinical transplantation
Mesenchymal stromal cell are the most studied clinical
cellular therapy in the field of organ transplantation so
far. MSC are a heterogeneous population of multipotent
cells usually obtained after ex vivo expansion of bone
marrow (BM), adipose tissue and umbilical cord (UC).
In the last decades, MSC have raised the interest of
transplant immunologists because they display unique
immunomodulatory activities. In several preclinical
models of transplantation, MSC prolonged graft survival
and induced tolerance to skin [12], heart [13,14], kid-
ney [15,16], islet [17] and corneal allografts [18,19].
Although short-lived after intravenous infusion [20],
MSC promote long-term immunomodulation by con-
ferring a pro-tolerogenic phenotype to regulatory T
cells, tolerogenic antigen-presenting cells (APC) and M2
macrophages [14,17,18,21].
Mesenchymal stromal cell immunomodulatory prop-
erties highly depend on the microenvironment they
encounter upon administration. Indeed, MSC exposed
to particular inflammatory signals can acquire an oppo-
site function, promoting inflammation [16,22] and act-
ing as APC following MHC-II upregulation [23]. One
of the major determinants of the effect of MSC is the
timing of administration [16,22]. It appears from pre-
clinical models that pretransplant infusion of MSC pro-
longs allograft survival, whereas infusion within days
after transplantation promotes alloreactivity [16].
Phase I clinical studies, primarily aimed at assessing
safety and feasibility of MSC, have been conducted in
kidney [24–28], liver [29–31], lung [32,33] and small-
bowel [34,35] transplantation. In all studies, MSC, iso-
lated either from autologous [24–28,34] or allogeneic
[30,32,33] BM or from UC [29,31], demonstrated an
exceptional safety profile. Administration of 1–2 9 106
autologous BM-MSC/kg was first performed in two liv-
ing-donor kidney transplant patients seven days after
transplantation [25]. Unexpectedly, both patients devel-
oped transient acute graft insufficiency. After amend-
ment of the protocol, the two subsequent patients
received BM-MSC the day before transplantation and
no longer experienced engraftment syndrome [24]. At
5- to 7-year follow-up, both patients maintained stable
graft function [28] and one recipient developed a long-
lasting immune profile characterized by an increased
regulatory T-cell/memory CD8+ T-cell ratio. Increased
regulatory T-cell expansion was also observed in living-
donor kidney transplant recipients receiving double
intravenous injections of autologous BM-MSC one day
before and 30 days post-transplant [27]. A study in six
living-donor kidney transplant patients employed MSC
therapy as a treatment for subclinical rejection and
interstitial fibrosis/tubular atrophy (IF/TA) [26].
Patients received two intravenous infusions of autolo-
gous BM-MSC, 7 days apart. Surveillance biopsies per-
formed in two MSC-treated recipients after MSC
infusion showed complete resolution of subacute cellu-
lar rejection (tubulitis) and IF/TA, suggesting that MSC
could protect the kidney graft from chronic damage
[26].
In liver transplantation, a prospective, controlled
phase I study showed safety and feasibility of a single
post-transplant intravenous injection of 1.5–3 9 106/kg
BM-MSC derived from a third-party donor. Rejection
rates, graft survival, histological findings on 6-month
protocol biopsies and Treg frequency in the peripheral
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blood during the 12-month follow-up were comparable
to control liver transplant patients [30]. Attempts to
wean immunosuppression failed in all but one patient
[30]. In the study by Shi et al. [29], liver transplant
recipients with biopsy-proven acute rejection receiving a
single intravenous infusion of 1 9 106/kg UC-MSC
showed a higher decrease in liver enzymes compared
with the control group receiving standard immunosup-
pression. In addition, increased circulating regulatory T-
cell frequencies and plasma levels of the immunoregula-
tory molecules TGF-beta and prostaglandin E2 (PGE2)
were detected in MSC-treated patients [29]. A study in
which UC-MSC were administered to 12 liver transplant
recipients with biliary complications at 1, 2, 4, 8 and
16 weeks after recruitment reported a significantly lower
need for clinical interventions and a higher 1-year graft
survival in MSC-treated patients compared with con-
trols [31].
In lung transplantation, a number of studies have
been conducted using allogeneic BM-MSC for amelio-
rating chronic lung allograft dysfunction. Chambers
et al. [32] reported a minor and transient fall in mean
arterial pressure and O2 saturation in patients with
chronic lung allograft dysfunction after injection of allo-
geneic BM-MSC. Compared with baseline, MSC-treated
patients showed a trend towards a slower decline in
forced expiratory volume after 1 year. A mild beneficial
effect of MSC on lung function was also reported by
Keller et al. [33]. A study in nine recipients with mod-
erate bronchiolitis obliterans syndrome (BOS) refractory
to standard therapy demonstrated no significant alter-
ations in pulmonary function 24 h, 1 week and
1 month after a single infusion of 1, 2 or 4 million
BM-MSC/kg [33]. At 1-year follow-up, five patients
exhibited a stabilization of lung function and three
patients showed a lesser rate of functional decline than
prior to MSC infusion. Patients given the lowest MSC
dose showed an increase in the frequency of Tregs and
a favourable pro-inflammatory/anti-inflammatory
plasma cytokine profile.
Finally, MSC have been tested in a small number of
patients undergoing small-bowel transplantation. A case
report described a patient with severe, refractory bowel
graft dysfunction after intestinal transplantation who
showed a rapid improvement in clinical parameters and
histological evidence of marked focal regenerative
changes after treatment with MSC [35]. In an additional
study, six patients underwent intestinal transplantation
and received 3 doses of autologous BM-MSC [34]. The
first dose of MSC was administered in the donor
intestinal artery during the transplant procedure, while
the second dose and third dose were injected into the
mesenteric artery 15 and 30 days post-transplant, with
no adverse effects.
These early studies demonstrated that MSC therapy is
safe and feasible in transplant patients, and evoked
interest in studies to the therapeutic effects of MSC
treatment in organ transplantation.
Towards phase 2–3 trials
The step from safety/feasibility studies towards phase 2–
3 trials slowly progressed over the last years. This may
be due to the fact that results of the early studies had to
be awaited, which seems wise, as proven safety and fea-
sibility are required for scaling up. Of interest, a lot has
been learned from individual case studies [24,25], which
helps the development of future studies. As mentioned
above, it was demonstrated that timing of MSC infusion
was of importance as an engraftment syndrome with
infiltration of immune cells and C3 deposits were found
when MSC were administered at 7 days after kidney
transplantation, which was not observed when MSC
were given before transplantation [24]. Moreover, an
interesting case provided evidence that in a renal trans-
plant recipient, infusion of autologous bone marrow
MSC was associated with safe complete discontinuation
of maintenance immunosuppression after transplanta-
tion allowing a state of immune tolerance [36]. Progres-
sion of the field is also influenced by logistic and
regulatory issues, which accompany cell-based therapy
such as clinical grade cell production facilities and asso-
ciated costs. As funding and equipment are lacking, it is
obvious that academic centres need support from a
commercial partner [37].
So far, there are few randomized controlled studies
with MSC although reference groups or whole cohorts
were included for comparability. In a phase 1–2 study
by Erpicum et al., the 1-year follow-up of a single infu-
sion of third-party MSC post-kidney transplantation in
addition to standard immunosuppression was reported.
This therapy was safe and associated with a transient
increase in regulatory T cells at day 30. It furthermore
improved early allograft function compared with the
control group and whole cohort [38]. Incidences of
opportunistic infections and acute rejection were similar
in the MSC group compared with controls. In this
study, four MSC-treated patients developed antibodies
against MSC or shared kidney-MSC HLA; however,
renal function remained stable leaving the clinical rele-
vance of this alloimmunization unclear. The develop-
ment of anti-HLA antibodies was not reported in a
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recent study where HLA selected allogeneic MSC were
infused with low-dose tacrolimus [39]. This design was
proven to be safe with a follow-up of 1 year after trans-
plantation [40]. In this study, no major alterations in
T- and B-cell populations or plasma cytokines were
observed upon MSC infusions.
The study by Tan et al. is the largest clinical trial
with MSC in the transplant setting so far. In a random-
ized controlled trial, it was demonstrated that treatment
with autologous BM-MSC, infused at day 0 and day 14
after transplantation, was safe and feasible as induction
therapy and allowed for calcineurin inhibitor reduction
[41]. In this study, immune monitoring was not per-
formed. The capability of MSC to allow reduction of
calcineurin inhibitors has also taken up by other groups.
In a study in living kidney transplantation with third-
party MSC (5 9 106/kg body weight at day 0 and
2 9 106/kg body weight at day 30) and a control group,
infusion of MSC was safe and allowed for a 50% reduc-
tion of calcineurin inhibitors. In this study, there was
no difference in circulating lymphocytes and in donor-
specific T-cell proliferation between the MSC group and
control group [42,43]. Most studies so far focused on
BM-MSC. A prospective multicentre randomized trial
in which MSC were intravenously infused at day 1
(2 9 106/kg body weight) and administered via the
renal artery during the kidney transplantation procedure
(5 9 106/kg body weight) in 21 patients vs. 21 controls
was performed with umbilical cord-derived MSC. This
study reported no difference in the incidence of delayed
graft function and acute rejection between the MSC
group and control group, and estimated glomerular fil-
tration rates were similar between the two groups [44].
There were no adverse clinical effects of MSC adminis-
tration. In this study, immune monitoring results were
not presented.
A recent phase 2–3 study recruited 70 patients in the
period 2014–2020 to test the hypothesis that MSC in
combination with the immunosuppressive everolimus
facilitates early withdrawal (at 8 weeks) of tacrolimus
with the aim to preserve renal function and structure.
The primary endpoint is fibrosis measured by quantita-
tive staining of Sirius Red. Secondary endpoints include
adverse events, including infections, renal function and
immune monitoring. Results are expected soon [45].
Interesting directions for future clinical trials with
MSC after renal transplantation include the timing and
frequency of MSC injections with the aim to limit fibro-
sis and alloimmune responses, to allow calcineurin inhi-
bitor withdrawal and probably induce a tolerogenic
state. Moreover, MSC infusion during organ
preservation may participate in limiting damage to the
graft [46].
Regulatory T cells
CD4+CD25+ regulatory T cells (Tregs) were discovered
over 20 years ago, and following the identification of
their master transcription factor, FOXP3 has become
central to major therapeutic developments in the fields
of autoimmunity, transplantation and cancer. There is
evidence for the existence of thymic Tregs (tTregs) in
bony fish some 400 million years ago [47], with periph-
erally induced Tregs (pTregs) following in placental
mammals where ‘on-demand’ regulation was required
to protect the foetus [48]. The vast array of Treg sup-
pressive mechanisms that have been identified may be
linked to the need for redundancy in the system [49].
This could be due to the need to control different cell
types through cell-specific mechanisms, or the many
environments in which Tregs are active [50]. However,
it is also possible that some of these identified mecha-
nisms are an artefact of the experimental system used to
investigate Treg activity, with in vitro suppression assays
highlighting effects such as the CD25/IL-2 consumption
phenomenon, that may not be as relevant in vivo [51].
Moreover, the ability to abrogate Treg function through
the deletion/blockade of specific genes or molecules
may, in fact, be a reflection of how easy it is to damage
a finely balanced system – removal of a single wheel
from a mechanical watch will break it – rather than
necessarily highlighting the functional importance of
these molecules.
Challenges in our understanding of the biology of
Tregs aside, these cells have enjoyed an accelerated clini-
cal development leading from mouse studies to phase II
trials in transplantation within only a few years (re-
viewed in Ref. [52]). The two principal clinical
approaches are to infuse autologous polyclonal ex vivo-
expanded Tregs, or to induce their expansion/generation
with the use of low-dose or mutein IL-2 treatment.
Clinical IL-2 therapy is largely being investigated in
autoimmunity [53], while in transplantation, adoptive
Treg therapy is more advanced (although there is now a
revival of interest in IL-2 treatment, and particularly
combined IL-2/Treg treatment, in transplantation [54–
56]). Enthusiasm for Tregs stems from the potential
advantage of modifying the balance between effector
and regulatory cells towards a state, which is more per-
missive to partial immunosuppression withdrawal or
discontinuation [57]. Published data from Treg cell
therapy trials in transplantation provide some cause for
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cautious optimism, with evidence for safety and perhaps
a reduced requirement for induction immunosuppres-
sion in renal transplantation [58] or even maintenance
immunosuppression in liver transplantation [59]. A
recent study in 11 kidney transplant patients demon-
strated that stable monotherapy immunosuppression
was achieved in 8 patients receiving autologous Treg
[60]. While these trials are still in early phases, the ben-
efits of reducing immunosuppression are becoming
apparent in terms of lower viral infection rates and nor-
malization of immune composition [58]. Encouragingly,
despite the wide variety of techniques being used to
produce these adoptive Treg cell therapies (e.g. [61–63])
and the anxiety regarding Treg stability and cell product
purity, no detrimental effects of infusion have yet been
detected, although the small number of patients treated
with Treg so far cannot rule out this possibility com-
pletely. Increased alloantibody responses observed in
lymphodepleted nonhuman primate heart allograft
recipients after infusion of Tregs shortly after transplan-
tation [64] and the report of the development of fever
and transient neutropenia, lymphopenia and mild liver
graft dysfunction in a patient after Treg administration
[65] demonstrate that safety of Treg therapy has to be
monitored at all times.
In the light of the excellent short-term results after
transplantation, later phase trials will need to be
designed carefully to ascertain whether Tregs are truly
effective [66,67]. Immune monitoring data are therefore
critical for identifying subtle changes in immune com-
position that may not manifest in early clinical out-
comes [68]. The wealth in genetic and cellular data
related to transplant rejection and regulation that have
been collected over decades will form an important
basis for identifying such changes, through technologies
that can be standardized across centres [69–72].
Next-generation Treg therapeutics are now focused
on antigen specificity [73], with chimeric antigen recep-
tor (CAR) Tregs taking centre stage [74]. These cell
products allow for intricate modification in antigen
recognition, costimulation, and signalling domains, the-
oretically providing greater control of the desired effects
[75,76]. Trials of CAR Tregs are planned by a number
of commercial enterprises; therefore, the precise details
of these studies are not publicly available. Nevertheless,
while enthusiasm is justified, it is not yet entirely clear
whether CAR Tregs are indeed effective in humans (or
whether they will be active against memory responses
[77]). Moreover, their production is further compli-
cated by the need for complex genetic modification
[78], making polyclonal Tregs an attractively simple
proposition if their efficacy is confirmed. Nonetheless,
as with many cellular therapies, a significant challenge
remains in the production capacity/capability of Treg
therapeutics. As it stands, production is costly, is time-
intensive and requires substantial operator input [79].
Methodologies that address these challenges while main-
taining quality are of significant value. Research in this
aspect of production will be critical over coming years
in order to ensure Treg therapy can be viably adopted
into clinical transplantation practice.
Regulatory myeloid cells
Dendritic cells and macrophages are diverse in function
and contain a variety of subsets with different pheno-
typical and functional characteristics that possess
immune regulatory properties. Regulatory macrophages
comprise a subset of macrophages that is induced upon
stimulation of activated macrophages with a variety of
stimuli [80]. It has been described that Fcc receptor
stimulation on mouse Toll-like receptor-activated
macrophages induces these cells to produce immune
suppressive IL-10 rather than immune-activating IL-12,
and induces CD4+ T cells to produce IL-4 [81]. The
induction of regulatory macrophages that show
increased anti-inflammatory cytokine production in
combination with reduced pro-inflammatory cytokine
production has also been demonstrated upon costimula-
tion of activated macrophages with a wide variety of
other factors such as PGE2 in mouse macrophages [82]
and TGF-b [83] and IFN-c in human macrophages
[84]. The induction of regulatory properties in macro-
phages after phagocytosis of apoptotic cells is a mecha-
nism that is seen across species [85]. Regulatory
macrophages thus represent a family of macrophages
that has in common their role in controlling immune
responses and contribution to tissue homeostasis. Simi-
larly, regulatory dendritic cells, known as tolerogenic
dendritic cells in the transplantation field, are a subset
of dendritic cells that act in a variety of ways to pro-
mote transplant tolerance, nicely summarized by
Ochando et al. [86].
The tissue protective immune controlling property of
regulatory macrophages and dendritic cells make them
of interest for cellular therapy in organ transplantation.
Several studies have reported graft survival-promoting
or even tolerance-inducing effects of donor-derived
tolerogenic dendritic cells in murine models [87–89]. A
type of regulatory macrophage induced by stimulation
of peripheral blood monocytes by macrophage colony-
stimulating factor (M-CSF) and interferon-c (IFNc)
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prolonged allograft survival by 24 days in a mouse heart
transplant model [90]. Like the tolerogenic dendritic
cells, these regulatory macrophages were of donor ori-
gin, and recipient or 3rd-party regulatory macrophages
given 8 days before transplantation were not effective in
this model. A similar type of regulatory macrophage has
been suggested to be an effective suppressor of the
xenoimmune response [91]. Conde et al. [92] demon-
strated that CD40-CD40L blockade induces DC-SIGN-
expressing regulatory macrophages that are capable of
prolonging heart allograft survival.
The promising results from in vitro and preclinical
studies have led to the translation of these studies to clin-
ical trials. Early clinical experience with regulatory
macrophages in organ transplant patients stems from a
decade ago, when two living-donor kidney transplant
patients received donor-derived regulatory macrophages
a week prior to transplantation, which were induced by
stimulating human monocyte-derived macrophages with
IFN-c for 18–24 h [93]. The patients tolerated the cells
well and underwent kidney transplantation without com-
plications. There were no signs of rejection in the first
year after cell infusion. In follow-up studies, it was
demonstrated that kidney transplant patients who
received 2.5–7.5 9 106 regulatory macrophages seven
days before kidney transplantation showed elevated levels
of TIGIT+FOXP3+ regulatory T-cell subtype [94]. In one
patient, TIGIT+FOXP3+ regulatory T-cell levels were ele-
vated seven years after transplantation. Tolerogenic den-
dritic cells have also been introduced to the clinic in the
first phase 1/2 clinical trials [95]. In the recently pub-
lished ONE Study, living-donor kidney transplant
patients were treated with regulatory macrophages, and
autologous tolerogenic dendritic or regulatory T cells
[58]. Patients in the different cellular therapy groups
received the same immunosuppressive regimen and were
grouped and compared with a reference group. In the cell
therapy group, basiliximab induction was omitted and
mycophenolate mofetil tapering was allowed. The
replacement of basiliximab by cell therapy did not result
in elevated acute rejection rates or adverse clinical events.
The cell therapy group as a whole showed a lower infec-
tion rate compared with the reference group. Similar to
MSC and Tregs, there are hints for therapeutic efficacy of
regulatory myeloid cells in organ transplantation, which
needs further exploration in large controlled trials.
Other cell types and extracellular vesicles
In addition to immunomodulatory purposes, cellular
therapies in organ transplantation may also be applied
to replace functional cells in diverse organs, such as
hepatocytes, podocytes, tubular cells or alveolar cells.
Strategies to replace lost or injured cells by culture-ex-
panded therapeutic cells are complex because of accessi-
bility issues, poor in vitro proliferation of functional
cells and limited survival of exogenous cells after
administration. Ex vivo organ perfusion techniques may
offer a solution to some of these problems, as discussed
by Hosgood et al. in this focus issue. Furthermore,
extracellular vesicles may represent an alternative for
some aspects of cellular therapies. Extracellular vesicles
mimic some of the functional properties of cells, while
they behave differently with respect to biodistribution
and have no survival issues. Extracellular vesicles con-
tain a variety of molecules with regeneration-inducing
and immunomodulatory function, including proteins,
lipids, lRNAs and mRNAs [96]. Furthermore, the
membranes of extracellular vesicles contain membrane-
spanning proteins, including HLA, that also play a role
in the biological function of vesicles. It has been pro-
posed that extracellular vesicles are regulators of
immune responses [96] and it has been demonstrated
that administration of donor dendritic cell-derived vesi-
cles prior to transplantation prolongs heart allograft
survival in a murine model [97].
Mesenchymal stromal cell are potent secretors of
extracellular vesicles [98]. MSC-derived vesicles have
been indicated to possess immune regulatory proper-
ties [99], prolong graft survival in vascularized com-
posite allotransplantation [100] and stimulate
angiogenic processes [101]. Therefore, extracellular
vesicles isolated from conditioned medium of cultured
MSC may be used for therapy development. One of
the challenges would be to isolate these vesicles free
from contaminating soluble proteins, as these accu-
mulate in the same fractions as vesicles using conven-
tional centrifugation and filtration techniques [102].
Currently, extracellular vesicles have not been exam-
ined in the context of clinical trials, although a num-
ber of studies have examined the effect of vesicles on
isolated animal and human organs, demonstrating a
potential reparative effect of vesicles [103]. In addi-
tion to collecting extracellular vesicles from cell cul-
ture supernatants, it is possible to generate vesicles
from the membranes of MSC or other cell types.
These vesicles can be generated in large numbers free
from contamination by soluble proteins, and interact
with cells of the immune system [104]. They may
therefore represent an up-scalable alternative to extra-
cellular vesicles.
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A summary of the major outcomes of clinical studies
in transplant patients with the major cell types is shown
in Table 1.
Endpoints and monitoring of cellular therapies
A very challenging aspect of clinical trials with cellular
therapy is to define endpoints that can measure safety,
feasibility and efficacy accurately and to monitor the
treatment. So far, trials in transplantation with cells
mainly focused on feasibility and safety, although sec-
ondary endpoints were included with a focus on mecha-
nistic insight [105]. For safety, potential risks include
direct toxicity related to the cell infusion and over-im-
mune suppression resulting in (opportunistic) infections
and malignancies. These should all be accurately moni-
tored and documented. It is advised to document the
(serious) adverse events (SAE) according to MedDRA
(Medical Dictionary for Regulatory Activities), which is
the international medical terminology developed under
the auspices of the International Council for Harmo-
nization of Technical Requirements for Pharmaceuticals
for Human Use. This method has been used in two
recently published trials with cell therapy in renal trans-
plantation and allows for comparison between trials
[40,58]. Since the development of infections and malig-
nancies may take time, long-term follow-up of patients
is required after finalizing clinical trials.
Allogeneic cells have numerous advantages compared
with autologous cells. Indeed, they are directly available
and allogeneic cell products can be easily standardized.
However, allogeneic cells can induce alloimmune
responses [38], which might increase the risk for allo-
graft rejection and graft dysfunction. Therefore, in trials
with allogeneic cells, analysis of anti-human leucocyte
antigen-specific antibodies related to allogenic MSC
infusions should be performed [40].
Traditional primary efficacy endpoints for novel
immunosuppressants in solid organ transplantation
focus on patient death, graft failure, biopsy-proven
acute rejection (BPAR) and graft (dys)function (defined
by criteria as measurement of creatinine/inulin clearance
for kidney dysfunction). Although these endpoints have
clear roles in research that aims to improve short-term
clinical outcomes, inhibition of early rejection does not
translate into long-term graft improvement. Moreover,
graft failure is rare in the early years after transplanta-
tion, and acute rejection rates have markedly declined.
In addition, trials with cellular therapy are labour-inten-
sive and costly, and trials with conventional endpoints
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challenge. As an example, to assess BPAR rates as pri-
mary objective, a patient population of at least 320
patients is needed to obtain a reduction of 50% in
rejection rate, assuming a rejection rate of 20% in the
control group with two-tailed significance of 0.05 and
80% power (chi-quadrate test), in a prospective ran-
domized controlled trial [106]. For all these reasons,
surrogate endpoints for long-term graft function are
necessary. In large patient cohorts in renal transplanta-
tion, glomerular filtration rates (GFR), CKD stages, pro-
teinuria, appearance of dnDSA, histology of antibody-
mediated rejection, IFTA and transplant glomerulopathy
are all associated with heightened risk of late graft func-
tional decline/failure [107–109]. However, unfortu-
nately, there is no approved surrogate marker for long-
term graft function yet.
The Banff score is the standard setting for the pathol-
ogist to evaluate renal transplant biopsies [110]; how-
ever, with this score precise quantification of, for
example, interstitial fibrosis is difficult since it is semi-
quantitative and there is inter-observer variability [111].
In the randomized controlled Triton trial, a surrogate
quantitative marker for the degree of fibrosis was used
by assessing Sirius Red staining in renal biopsies, which
specifically stains collagen types I and III [112]. Indeed,
several studies showed that Sirius red staining can be
used as an accurate and reproducible method for mea-
suring the degree of interstitial fibrosis [113]. O’Connell
et al. [114] developed a panel consisting of 13 genes
that is highly predictive in kidney allograft biopsies for
the development of fibrosis at 1 year after transplanta-
tion. Such molecular panels may be used to adjust treat-
ment of transplant patients at an early stage.
In all trials, graft function is included as secondary
endpoint. As an example, in renal transplantation the
determination of renal function (GFR) is of importance
for assessing safety and for follow-up after cell-based
therapy. However, it is of importance to note that GFR
clearly has also limitations, since early subclinical dis-
ease, which may lead to late failure, is not captured.
Besides graft function, immune monitoring is crucial in
the evaluation of cellular therapy. The ONE Study con-
sortium developed a standardized method, which moni-
tors the general immune response and T-cell, B-cell and
dendritic cell subsets [70]. This method has been used
in the ONE Study, as well as in studies with MSC ther-
apy after renal transplantation [26,40,58]. In addition,
functional assays, such as the in vitro-mixed lymphocyte
reaction and measurement of cytokines, might give
mechanistic insight after cell therapy [106]. Other
described endpoints include cardiovascular mortality
and morbidity, as MSC have also been used for cardio-
vascular indications and might influence coexisting dis-
ease in the transplant recipient [45].
Recently, it was shown that combining factors as
composite surrogate endpoint probably better reflects
the heterogeneity of graft failure compared with single-
cell markers. Of interest, the iBOX score has recently
been validated in different patient cohorts and has
shown robustness in this respect [109]. This method
has not yet been applied in cell therapy trials.
Future perspectives
Cellular therapies are a promising novel way of treat-
ing immune- and injury-related complications in
organ transplant patients. Therapies with various cells
types with specific properties are under investigation
and may be applied for different indications. The
majority of trials so far have shown safety of cellular
therapies in organ transplant patients. The next
important step is to show efficacy of cellular thera-
pies. This involves up-scaling of GMP production of
therapeutic cells and performing large placebo-con-
trolled trials. Collaborations between academic centres
and industry are essential to achieve this. Further-
more, better understanding of biodistribution, survival
and interaction of administered cells with host cells is
crucial for the development of efficacious cellular
therapy. In contrast to past beliefs, exogenous cells
may not have a long lifespan after administration.
MSC have been shown to disappear largely within
24 h after intravenous administration and rather
instruct host cells to adapt a therapeutic phenotype
during their brief presence [20,115]. The study of
Roemhild et al. [60] reported a transient increase in
Treg levels with a return to control levels 12 weeks
after administration of Tregs. For other cell types,
survival times are not clear, and the use of autolo-
gous cells in clinical studies hampers long-term track-
ing.
In theory, some of these effects may be mediated via
nonviable therapeutic cell-derived products, such as sol-
uble proteins, vesicles with their membrane-bound pro-
teins or even intact dead cells. Another direction that
cellular therapies in the field of organ transplantation
may move to is to treat patients at early stages of organ
injury. Early treatment of inflammatory or degenerative
processes may repair organs and eventually make trans-
plantation obsolete. Results of studies in the near future
will determine in which way cellular therapies will
develop.
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